The observed enhancement of drug-sensitive cell proliferation and the involvement of E2F1 in stimulating the growth of this cell population provide valuable insights into potential mechanisms underlying the adaptation of cancer cells to the presence of resistant counterparts. This evidence concerns the gene E2F1 and cancer.